{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Untreated+Cohort&page=2", "query": { "intervention": "Untreated Cohort", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Untreated+Cohort&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T01:34:17.888Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04187404", "title": "A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adrenocortical Carcinoma", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "EO2401", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Enterome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2020-07-23", "completion_date": "2024-10-02", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04187404" }, { "nct_id": "NCT04396821", "title": "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "TST001", "type": "DRUG" }, { "name": "Nivolumab Injection [Opdivo]", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Albumin-Bound Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Transcenta Therapeutics (Hangzhou) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2020-05-28", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396821" }, { "nct_id": "NCT02266147", "title": "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Lymphoma" ], "interventions": [ { "name": "SD-101", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dynavax Technologies Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-10", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2020-09-04", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 5, "location_summary": "Stanford, California • Chicago, Illinois • Iowa City, Iowa + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02266147" }, { "nct_id": "NCT07508982", "title": "Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "APG1252", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2026-05-22", "completion_date": "2031-12-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07508982" }, { "nct_id": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-08-29", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 12, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593915" }, { "nct_id": "NCT04854499", "title": "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2021-09-07", "completion_date": "2024-10-02", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 22, "location_summary": "Chandler, Arizona • Duarte, California • Los Angeles, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854499" }, { "nct_id": "NCT00546897", "title": "Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 48, "start_date": "2007-02", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2014-09-29", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546897" }, { "nct_id": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "canakinumab", "type": "DRUG" }, { "name": "canakinumab-matching placebo", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 673, "start_date": "2018-12-21", "completion_date": "2026-01-26", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 4, "location_summary": "Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631199" }, { "nct_id": "NCT02446626", "title": "Xenodiagnosis After Antibiotic Treatment for Lyme Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lyme Disease" ], "interventions": [ { "name": "Skin biopsy", "type": "PROCEDURE" }, { "name": "Blood draw", "type": "PROCEDURE" }, { "name": "Xenodiagnosis", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2015-07-24", "completion_date": "2022-05-04", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 5, "location_summary": "Storrs, Connecticut • Bethesda, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Storrs", "state": "Connecticut" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446626" }, { "nct_id": "NCT00014495", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "bismuth Bi213 monoclonal antibody M195", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 32, "start_date": "2000-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-01-22", "last_synced_at": "2026-09-25T01:34:17.888Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014495" } ] }